NVO's Wegovy pill is estimated to own 89% of US GLP pill market share

"The report, based on IQVIA data for the week ended July 3, showed the Wegovy pill generated about 153,050 U.S. prescriptions, compared with roughly 19,550 for Foundayo. That gave Novo Nordisk an estimated 89% share of prescriptions for the two once-daily oral obesity medicines, while Eli Lilly accounted for about 11%." (source above) End of June, LLY issued concerns on the US' pricing policy and stated that the EU launch will most likely impact the Foundayo pill profitability: "A

CryptoAlerta — análise de criptomoedas e mercado em tempo real